Why Psychedelic Stocks Have Crashed in the Last 3 Months
Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
Day: October 13, 2021
FDA Backs Ketamine to Treat This Rare and Debilitating Pain Syndrome
Food and Drug Administration grants psychedelic biotechnology company PharmaTher orphan drug designation for ketamine to treat complex regional pain syndrome.
Interview with Joseph Mays, IRI Program Director at Chacruna
In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.
End of content
End of content